AMJ

Could an eye scan help detect Alzheimer's before symptoms take hold?

AI retinal imaging is being evaluated as a referral tool in primary care - and the rationale is compelling.

See the findings: https://hubs.la/Q04jnW270

Persistent taste and smell dysfunction is rare after ICI therapy for cancer- but some patients claim to experience these effects.

Find out why: https://hubs.la/Q04jnSd90

A deadly Andes virus outbreak is renewing focus on hantavirus preparedness.

There are still no approved vaccines or targeted treatments for Andes virus, despite decades of research.

Our latest carousel explores:
• Why this outbreak matters
• The challenges slowing vaccine development
• Why early recognition remains critical

Read the full findings: https://hubs.la/Q04jbYwB0

Explore our 3 must-reads for Lupus Awareness Month

From the gut microbiome to precision immunotherapy and emerging biomarkers, discover the latest insights shaping the future of lupus care.

🦠 Explore the gut–lupus connection:
How the Gut Microbiota Shapes Lupus Activity
🔗: https://hubs.la/Q04h_JlP0

🧬 Discover the future of lupus treatment:
Lupus Treatment Enters Precision Immunotherapy Era
🔗: https://hubs.la/Q04h_Xgj0

🔬 See the latest on lupus nephritis biomarkers:
Lupus Nephritis Biomarkers Still Face Barriers
🔗: https://hubs.la/Q04j0h_S0

Hot nights may be worsening asthma attacks.

New research linked extreme nighttime heat to higher asthma emergency visits in both adults and children.

Learn more:

Hot Nights Increase Emergency Department Visits in Asthma Extreme heat and asthma ED visits were linked in Baltimore. Read more on nighttime heat and neighborhood risk.

Early-career rheumatology nurses may be entering practice underprepared for complex patient care.

New research highlights major training and competency gaps in resource-limited settings.

Read more: https://hubs.ly/Q04hvQ9K0

At , researchers highlighted the Phase III ADVANCE OUTCOMES trial evaluating ralinepag in pulmonary arterial hypertension.

The global study is investigating whether once-daily prostacyclin pathway targeting can help slow disease progression in patients already receiving background therapy.

Read more:

ATS 2026: Ralinepag Trial Targets PAH Disease Progression Ralinepag is being evaluated in PAH patients receiving background therapy. Read more about the ADVANCE OUTCOMES trial.